上海复旦复华科技股份有限公司（以下简称"公司"）于 2024 年 5 月 30 日收到 了上海国际经济贸易仲裁委员会（上海国际仲裁中心）寄来的《<关于宁波美丽人生 医药生物科技发展有限公司之股权收购协议>争议仲裁案仲裁通知（上国仲（2024） 第 1492 号）》（以下简称"仲裁通知"）及仲裁申请书等相关法律文书，现将相关情 况公告如下： 一、本次仲裁的情况 （一）本次仲裁所涉事项的基本情况 证券代码：600624 证券简称：复旦复华 公告编号：临 2024-023 上海复旦复华科技股份有限公司 涉及仲裁的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 为增强公司盈利能力、综合竞争能力和持续发展能力，扩充医药产业链、形成 业务协同，公司于 2022 年 4 月 28 日召开的第十届董事会第十二次会议审议通过了 《关于收购宁波美丽人生医药生物科技发展有限公司 51%股权的议案》，董事会同意 公司以自筹资金的方式出资人民币 114,192,102.03 元收购标的公司 51%股权，并签 订了《关于宁波美 ...

上海复旦复华科技股份有限公司 2023 年年度股东大会会议资料 证券代码：600624 证券简称：复旦复华 上海复旦复华科技股份有限公司 2023 年年度股东大会会议资料 二〇二四年六月 1 | | | 2023年年度股东大会议程 现场会议召开时间：2024 年 6 月 5 日下午 2 点整 现场会议地点：上海市奉贤区茂园路 50 号 37 号楼 16 楼会议室 出席人员：1、2024 年 5 月 30 日下午交易结束后登记在册的本公司股东及其授权 委托人； 2、公司董事、监事、高管人员及聘任的股东大会见证律师。 会议议程： 一、介绍出席会议的股东人数及其代表的股份总数。 | 年年度股东大会议程 | 2023 | 3 | | --- | --- | --- | | 年年度股东大会会议须知 | 2023 | 5 | | 年年度股东大会议案表决办法 | 2023 | 6 | | 年度董事会报告 | 2023 | 7 | | 年度监事会报告 | 2023 | 15 | | 年年度报告及报告摘要 | 2023 | 20 | | 年度财务决算报告 | 2023 | 21 | | 年度财务预算报告 | 2024 | 22 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 155,481,059.50, representing a decrease of 8.54% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of CNY 11,103,708.12, a significant decline of 7,050.69% year-over-year[5]. - The basic earnings per share (EPS) was -0.0162 CNY, reflecting a decrease of 8,200.00% compared to the previous year[6]. - The company reported a net loss of RMB 11,523,965.67 for Q1 2024 compared to a profit of RMB 134,242.64 in Q1 2023[18]. - The company reported a net loss of CNY 11,140,434.51 in Q1 2024, compared to a net profit of CNY 284,018.59 in Q1 2023, indicating a significant decline in performance[21]. - The company reported a total comprehensive loss of CNY -14,677,497.18 in Q1 2024, compared to a total comprehensive loss of CNY -3,853,463.87 in Q1 2023[22]. - Basic and diluted earnings per share were both CNY -0.0162 in Q1 2024, compared to CNY 0.0002 in Q1 2023, reflecting a significant decline in profitability per share[22]. Cash Flow and Assets - The net cash flow from operating activities was -CNY 44,759,734.75, indicating a negative trend in cash generation from core operations[5]. - The company experienced a net cash outflow from operating activities of CNY -44,759,734.75 in Q1 2024, compared to CNY -12,328,043.58 in Q1 2023, indicating worsening cash flow issues[25]. - Cash and cash equivalents decreased to RMB 234,857,012.06 from RMB 305,482,145.68 as of December 31, 2023, representing a decline of 23.1%[16]. - Cash and cash equivalents at the end of Q1 2024 stood at CNY 233,660,080.86, down from CNY 253,122,223.69 at the end of Q1 2023, representing a decrease of approximately 7.7%[26]. - Total assets at the end of the reporting period were CNY 1,714,141,972.94, down 4.63% from the previous year[6]. - Total current assets decreased to RMB 989,098,406.01 from RMB 1,064,716,305.51, a decline of 7.1%[16]. - Total non-current assets decreased to RMB 725,043,566.93 from RMB 732,572,863.01, a reduction of 1.04%[17]. - Total liabilities decreased to RMB 883,873,302.52 from RMB 951,788,500.73, a decline of 7.1%[18]. - Total equity decreased to RMB 830,268,670.42 from RMB 845,500,667.79, a reduction of 1.8%[18]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 61,872[12]. - The largest shareholder, Shanghai Fengxian Investment (Group) Co., Ltd., held 18.74% of the shares[12]. Operational Metrics - Total revenue for Q1 2024 was RMB 155,481,059.50, a decrease of 8.93% compared to RMB 170,001,077.38 in Q1 2023[20]. - Total operating costs for Q1 2024 were RMB 168,920,960.50, slightly decreased from RMB 168,935,699.01 in Q1 2023[20]. - Total revenue from operating activities decreased to CNY 169,522,557.27 in Q1 2024, down from CNY 194,114,784.34 in Q1 2023, reflecting a year-over-year decline of approximately 12.6%[25]. - The company's operating profit turned negative at CNY -12,093,127.17 in Q1 2024, compared to a positive operating profit of CNY 3,310,585.41 in the same period last year[21]. - Research and development expenses decreased to CNY 8,191,675.26 in Q1 2024 from CNY 9,253,798.88 in Q1 2023, showing a reduction of about 11.5%[21]. Financial Expenses and Impairments - The company incurred financial expenses of CNY 3,859,616.48 in Q1 2024, an increase from CNY 2,477,266.26 in Q1 2023, marking a rise of approximately 55.7%[21]. - The company’s total assets impairment losses were reported at CNY 398,083.76 in Q1 2024, compared to CNY 1,064,619.84 in Q1 2023, indicating a decrease in asset impairment losses[21]. Strategic Focus - The company is focusing on improving its financial performance and exploring new strategies to enhance market presence[10].

Financial Performance - The net profit attributable to shareholders for 2023 is RMB 5,962,951.73, a significant recovery from a loss of RMB 6,200,241.81 in 2022[4] - Total operating revenue for 2023 is RMB 679,678,938.29, representing a decrease of 13.86% compared to RMB 789,005,422.13 in 2022[19] - The net cash flow from operating activities decreased by 75.01% to RMB 7,033,862.40 from RMB 28,146,459.61 in the previous year[19] - The total assets as of the end of 2023 are RMB 1,797,289,168.52, down 3.75% from RMB 1,867,389,132.02 at the end of 2022[19] - The net assets attributable to shareholders increased slightly to RMB 804,800,130.55, a 0.14% increase from RMB 803,688,525.35 in 2022[19] - Basic earnings per share for 2023 is RMB 0.009, recovering from a loss of RMB 0.009 in 2022[20] - The weighted average return on equity for 2023 is 0.74%, a recovery from -0.75% in 2022[20] - The company reported a significant adjustment in financial data due to prior accounting errors, impacting the reported figures for previous years[24] - The company reported a net profit of CNY 6,796,879.87, a substantial recovery from a loss of CNY 1,931,716.33 in the previous year[65] - The total profit increased by 2,096.98% to CNY 23,482,524.96, driven by gains from asset disposals and improved performance from subsidiaries[64] Revenue and Segment Performance - The company's total revenue for the reporting period was 679.68 million yuan, a decrease of 13.86% compared to the same period last year[32] - The pharmaceutical segment generated revenue of 342.04 million yuan, a decrease of 14.22%, accounting for 50.32% of total revenue[32] - The software segment's revenue was 270.73 million yuan, a decrease of 4.56%, contributing 39.83% to total revenue[34] - The park segment's revenue was 40.12 million yuan, a significant decrease of 50.50%, representing 5.90% of total revenue[36] - The company’s total operating revenue for digestive system drugs was CNY 177.57 million, a decrease of 20.09% year-on-year, with a gross margin of 72.90%[125] - Total operating revenue for neurological system drugs was CNY 81.66 million, a decrease of 8.14% year-on-year, with a gross margin of 43.74%[125] - Total operating revenue for anti-tumor drugs was CNY 12.10 million, a significant decrease of 51.00% year-on-year, with a gross margin of 65.64%[125] Cost Management and Expenses - Operating costs amounted to CNY 385,368,876.25, down 16.53% year-on-year[61] - The company's financial expenses decreased by 26.63% to CNY 14,818,205.67, reflecting better cost management[61] - The income tax expense rose by 456.08% to CNY 16,685,645.09, mainly due to increased taxes from asset sales[65] - The total sales expenses for the reporting period were 14,249.69 million RMB, which is a decrease of 12.06% compared to the previous year[136] - The sales expense ratio increased by 0.97% to 41.61%, slightly higher than the industry average[136] Research and Development - The company increased its R&D investment, completing the project initiation for one new product during the reporting period[33] - R&D investment totaled 41,400,546.18 RMB, accounting for 6.09% of operating revenue, with capitalized R&D making up 15.18% of total R&D investment[80] - The company is focusing on the quality and efficacy consistency evaluation of 289 listed products, with key evaluations completed for several products in 2023[127] - The company is actively pursuing consistency evaluations for several products, including Isosorbide Dinitrate Tablets and Bicalutamide Tablets[133] - The company’s R&D investment for the reporting period amounted to 2,912.48 million RMB, representing 6.80% of the pharmaceutical revenue[133] Market and Industry Trends - The pharmaceutical manufacturing industry achieved a revenue of CNY 2,520.57 billion, a year-on-year decrease of 3.7%[39] - The total profit for the pharmaceutical manufacturing sector was CNY 347.30 billion, reflecting a year-on-year decline of 15.1%[39] - The retail sales of Chinese and Western medicines reached CNY 671 billion in 2023, growing by 5.1% year-on-year[40] - The software industry in China generated software business revenue of CNY 12,325.8 billion in 2023, marking a year-on-year increase of 13.4%[44] - The company is facing challenges due to policy changes in the pharmaceutical industry, leading to a decline in operating performance[54] Strategic Initiatives and Future Outlook - Future outlook includes continued efforts in market expansion and potential new product development to drive revenue growth[21] - The company aims to increase the number of high-quality incubators to 20 and daily new tech enterprises to 200 by 2025, contributing to the growth of emerging industries[50] - The company plans to enhance its pharmaceutical segment by increasing R&D investment and expanding its product line, focusing on specialty and traditional Chinese medicine[165] - The company is actively exploring mergers and acquisitions to diversify its client base and business areas, aiming for asset appreciation and cost reduction[168] - The company anticipates total revenue of 750 million yuan for 2024, with expected operating costs of 420 million yuan and expenses of 320 million yuan[167] Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective decision-making and protection of shareholder interests[177] - The board of directors held 7 meetings, with independent directors constituting at least one-third of the board, ensuring compliance with legal requirements[178] - The company has implemented a robust internal control system to enhance management levels and risk prevention capabilities, aligning with its operational needs[181] - The company has not found any insider trading incidents among its directors, supervisors, and senior management during the reporting period[183] - The company has a diverse board with a mix of genders and ages, with the youngest director being 30 years old and the oldest being 61 years old[189]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所发布的上市公司分行业信息披露指引《上海证券交易所 上市公司自律监管指引第 3 号——行业信息披露》及《关于做好主板上市公司 2024 年第一季度报告披露工作的重要提醒》相关要求，上海复旦复华科技股份 有限公司下属子公司上海复旦复华药业有限公司 2024 年第一季度主要经营数据 披露如下： | 主营业务分行业情况 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 分行业 | 营业收入 | 营业成本 | 毛利率 （%） | 营业收入 比上年增 | 营业成本 比上年增 | 毛利率比 上年增减 | | | | | | 减（%） | 减（%） | （%） | | 药业 | 77,001,457.59 | 32,066,659.11 | 58.36 | -9.31 | -9.12 | -0.08 | | 主营业务分产品情况 | | | | | | | | 分产品 | 营业收入 | 营业成本 | 毛利 ...

上海复旦复华科技股份有限公司（以下简称"公司"或"复旦复华"）于近期 收到中国证券监督管理委员会上海监管局下发的《关于对上海复旦复华科技股份有 限公司采取责令改正措施的决定》（沪证监决〔2024〕94 号）（以下简称"《决定 书》"），上海证监局决定对公司采取责令改正的行政监管措施，并要求公司对《决 定书》指出的问题进行整改。具体详见公司于 2024 年 3 月 20 日在上海证券交易所 网站（www.sse.com.cn）披露的《上海复旦复华科技股份有限公司关于收到中国证 券监督管理委员会上海监管局＜行政监管措施决定书＞的公告》。 收到《决定书》之后，公司高度重视，向公司全体董事、监事、高级管理人员 （以下简称"董监高"）及相关人员进行了通报、传达，并召集相关部门和人员对 《决定书》中涉及的问题进行了全面梳理和针对性地分析讨论，同时根据相关法律 法规、规范性文件及公司各项管理制度的规定和要求，结合公司实际情况，按照《决 定书》中的要求逐项梳理并认真落实整改措施。 公司于 2024 年 4 月 16 日以通讯方式召开公司第十一届董事会第二次会议，本 次会议的通知和资料已于 2024 年 4 月 12 日送达全 ...

上海复旦复华科技股份有限公司（以下简称"公司"）于 2024 年 4 月 1 日收到 《上海铁路运输法院民事判决书（（2023）沪 7101 民初 500 号）》，现将相关情况公 告如下： 一、本次诉讼的基本情况 1、公司于 2023 年 3 月 15 日收到了《上海铁路运输法院应诉通知书（（2023） 沪 7101 民初 500 号）》及民事起诉状等相关法律文书，上海泉淳实业发展有限公司 因单位借款合同纠纷对公司提起诉讼。详见公司于 2023 年 3 月 17 日披露的《上海 复旦复华科技股份有限公司涉及诉讼的公告》。 2、公司于 2024 年 1 月 16 日收到《上海铁路运输法院民事裁定书（（2023）沪 7101 民初 500 号）》，申请人上海泉淳实业发展有限公司向上海铁路运输法院申请， 请求继续保全被申请人上海复旦复华科技股份有限公司银行存款 31,973,361.11 元 或查封、扣押其相应价值的财产，并已提供保单保函作为担保。上海铁路运输法院 1 案件所处的诉讼阶段：一审判决 上市公司所处的当事人地位：被告 涉案金额：人民币 2,000 万元整及利息 是否会对上市公司损益产生负面影响：鉴于涉诉 ...

证券代码：600624 证券简称：复旦复华 公告编号：临 2024-007 上海复旦复华科技股份有限公司 关于股东股份被轮候冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 上海上科科技投资有限公司（以下简称"上科科技"）为上海复旦复华科技 股份有限公司（以下简称"公司"）持股 5%以上非控股股东。截至公告披 露日，上科科技持有公司股份共计 69,206,536 股，占公司总股本的 10.1074%，其中质押的公司股份数量为 69,202,880 股，占其所持公司股份 总数的 99.9947%，占公司总股本的 10.1069%。本次上科科技被轮候冻结股 份总计 69,206,536 股，占其所持公司股份的 100%。 公司于 2024 年 3 月 19 日收到中国证券登记结算有限责任公司上海分公司出具 的《股权司法冻结及司法划转通知（2024 司冻 0315-1 号）》及上海市第一中级人民 法院出具的《协助执行通知书》（2024）沪 01 民初 80 号，公司股东上科科技所持有 的公司 69,2 ...

证券代码：600624 证券简称：复旦复华 公告编号：临 2024-003 上海复旦复华科技股份有限公司 关于涉及诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 上海复旦复华科技股份有限公司（以下简称"公司"）于 2024 年 1 月 16 日收到 《上海铁路运输法院民事裁定书（（2023）沪 7101 民初 500 号）》（以下简称"民事 裁定书"），现将相关情况公告如下： 一、案件的基本情况 公司于 2023 年 3 月 15 日收到了《上海铁路运输法院应诉通知书（（2023）沪 7101 民初 500 号）》及民事起诉状等相关法律文书，上海泉淳实业发展有限公司因 单位借款合同纠纷对公司提起诉讼（详见公司于 2023 年 3 月 17 日披露的临 2023-006 《上海复旦复华科技股份有限公司涉及诉讼的公告》）。 二、本次诉讼案件的进展情况 （一）民事裁定书主要内容 申请人：上海泉淳实业发展有限公司 被申请人：上海复旦复华科技股份有限公司 法院：上海铁路运输法院 1 案件所处的诉讼阶 ...

证券代码：600624 证券简称：复旦复华 公告编号：临 2024-004 上海复旦复华科技股份有限公司 关于部分银行账户被冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海复旦复华科技股份有限公司（以下简称"公司"）财务人员于 2024 年 1 月 17 日通过查询网银获悉公司存在新增银行账户被冻结的情况，具体如下： | 户名 | 开户行 | 账户性质 | 账号 | 账户余额 | | --- | --- | --- | --- | --- | | | | | | （元） | | 上海复旦复华科技股 | 招商银行股份有限公 | 一般户 | 0219*******0305 | 2,935.41 | | 份有限公司 | 司上海四平支行 | | | | 一、本次新增冻结账户的基本情况 二、本次银行账户被冻结的原因 公司于 2022 年 7 月 8 日收到了《上海市静安区人民法院通知（（2022）沪 0106 民诉前调 7157 号）》及民事起诉状等相关法律文书，上海泉淳实业发展有限公司因 与上海复华创业投资有限公 ...